MCID: VLV010
MIFTS: 42

Vulvovaginitis malady

Categories: Reproductive diseases

Aliases & Classifications for Vulvovaginitis

Aliases & Descriptions for Vulvovaginitis:

Name: Vulvovaginitis 12 52 42 14 69
Vulvo-Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2273
ICD10 33 N76.0
MeSH 42 D014848
NCIt 47 C35131
UMLS 69 C0042998

Summaries for Vulvovaginitis

MalaCards based summary : Vulvovaginitis, also known as vulvo-vaginitis, is related to vulvovaginal candidiasis and vulvovaginal gingival syndrome. An important gene associated with Vulvovaginitis is HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and neutrophil.

Wikipedia : 71 Vaginitis, also known as vaginal infection and vulvovaginitis, is an inflammation of the vagina and... more...

Related Diseases for Vulvovaginitis

Diseases related to Vulvovaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
id Related Disease Score Top Affiliating Genes
1 vulvovaginal candidiasis 12.3
2 vulvovaginal gingival syndrome 12.0
3 vulvovaginal rhabdomyosarcoma 11.9
4 vaginitis 11.3
5 vulvar vestibulitis syndrome 11.1
6 candidiasis 10.8
7 vulvar disease 10.8
8 postmenopausal atrophic vaginitis 10.8
9 vaginal disease 10.8
10 myeloid splenomegaly 10.2 CXCL8 HSPD1
11 psychotic disorder 10.2 CCL11 CXCL8
12 retinal vascular disease 10.2 CCL11 CXCL8
13 hydrophthalmos 10.1 CCL11 CXCL8
14 pancreatic signet ring cell adenocarcinoma 10.1 HSPD1 IL10
15 denys-drash syndrome 10.1 HSPD1 IL10
16 conidiobolomycosis 10.1 CXCL8 IL10
17 inflammatory bowel disease 20 10.1 CXCL8 IL10
18 follicular adenoma 10.1 HSPD1 IL10
19 neonatal hypoxic and ischemic brain injury 10.1 CXCL8 IL10
20 coronary arterial fistulas 10.1 CXCL8 IL10
21 childhood electroclinical syndrome 10.1 CXCL8 IL10
22 middle lobe syndrome 10.1 CXCL8 IL10
23 plantar wart 10.1 CXCL8 IL10
24 bacterial vaginosis 10.1
25 trichomalacia 10.1 CXCL8 IL10
26 senile reticular retinal degeneration 10.1 CXCL8 IL10
27 gastric dilatation 10.1 CXCL8 IL10
28 fallopian tube serous adenocarcinoma 10.1 CXCL8 IL10
29 autosomal recessive type iv ehlers-danlos syndrome 10.1 CXCL8 IL10
30 tracheitis 10.1 CCL11 CXCL8
31 immunodeficiency due to a late component of complement deficiency 10.1 CXCL8 IL10
32 inappropriate adh syndrome 10.1 CXCL8 IL10
33 thyroid hyalinizing trabecular adenoma 10.1 CCL11 CXCL8
34 labyrinthitis 10.1 CXCL8 IL10
35 atrophy of prostate 10.1 CXCL8 IL10
36 myiasis 10.1 CXCL8 IL10
37 alcoholic hepatitis 10.1 CXCL8 IL10
38 childhood central nervous system mixed germ cell tumor 10.1 CXCL8 IL10
39 chordoid meningioma 10.0 CXCL8 IL10
40 choroiditis 10.0 CXCL8 IL10
41 latent syphilis 10.0 CCL11 CCL5
42 lichen planus 10.0
43 entropion 10.0 CXCL8 IL10
44 cerebral primitive neuroectodermal tumor 10.0 CCL11 CCL5
45 apricot allergy 10.0 CCL11 CCL5
46 trachea leiomyoma 10.0 CCL11 CCL5
47 visceral steatosis 10.0 CCL11 CCL5
48 cutaneous fibrous histiocytoma 10.0 CCL11 CCL5
49 depressed scar 10.0 CXCL8 IL10
50 orofacial granulomatosis 10.0 CCL5 HSPD1

Graphical network of the top 20 diseases related to Vulvovaginitis:



Diseases related to Vulvovaginitis

Symptoms & Phenotypes for Vulvovaginitis

Drugs & Therapeutics for Vulvovaginitis

Drugs for Vulvovaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
3 Dequalinium Approved Phase 4 6707-58-0
4
Fluconazole Approved Phase 4,Phase 3,Phase 2 86386-73-4 3365
5
Terconazole Approved Phase 4 67915-31-5 441383
6
Clindamycin Approved, Vet_approved Phase 4,Phase 3 18323-44-9 29029
7
Ephedrine Approved Phase 4 299-42-3 9294
8
Pseudoephedrine Approved Phase 4 90-82-4 7028
9 Antifungal Agents Phase 4,Phase 3,Phase 2
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2
11 Anti-Infective Agents, Local Phase 4,Phase 3
12 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2
13 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3
14 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
15 Hormone Antagonists Phase 4,Phase 3,Phase 2
16 Hormones Phase 4,Phase 3,Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
18 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
20 Clindamycin palmitate Phase 4,Phase 3
21 Clindamycin phosphate Phase 4,Phase 3
22 Tetrahydrozoline Phase 4,Phase 3
23 Antibiotics, Antitubercular Phase 4
24 Antitubercular Agents Phase 4
25 Autonomic Agents Phase 4
26 Nasal Decongestants Phase 4
27 Ophthalmic Solutions Phase 4
28 Peripheral Nervous System Agents Phase 4
29 Pharmaceutical Solutions Phase 4,Phase 2
30 Respiratory System Agents Phase 4
31 Vasoconstrictor Agents Phase 4
32
Butoconazole Approved Phase 3 64872-77-1, 64872-76-0 47472
33
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 14956 5280965
34
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
35
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
36 Antiparasitic Agents Phase 3,Phase 2
37 Antiprotozoal Agents Phase 3,Phase 2
38 Liposomal amphotericin B Phase 3,Phase 2
39
Aluminum hydroxide Approved Phase 1, Phase 2 21645-51-2
40 Adjuvants, Immunologic Phase 1, Phase 2
41 Antacids Phase 1, Phase 2
42 Anti-Ulcer Agents Phase 1, Phase 2
43 Gastrointestinal Agents Phase 1, Phase 2
44 Vaccines Phase 1, Phase 2
45 Acidophilus Nutraceutical Phase 1,Early Phase 1
46
Iron Approved 7439-89-6 23925
47
Itraconazole Approved, Investigational 84625-61-6 55283
48
Metronidazole Approved 443-48-1 4173
49 Hydroxyitraconazole
50 Micronutrients

Interventional clinical trials:

(show all 43)
id Name Status NCT ID Phase
1 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
2 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4
3 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4
4 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4
5 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4
6 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4
7 Vaginal Infection Study Completed NCT00616330 Phase 3
8 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3
9 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3
10 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3
11 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3
12 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3
13 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3
14 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Not yet recruiting NCT03005353 Phase 2, Phase 3
15 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3
16 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2
17 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2
18 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
19 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2
20 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2
21 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2
22 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Recruiting NCT02971007 Phase 2
23 TOL-463 Phase 2 Study for Vaginitis Active, not recruiting NCT02866227 Phase 2
24 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Active, not recruiting NCT02267382 Phase 2
25 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2
26 Patients With Vulvovaginal Candidiasis Not yet recruiting NCT03024502 Phase 1, Phase 2
27 Efficacy Vulvovaginitis Candida Terminated NCT00199264 Phase 2
28 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
29 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
30 Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy Completed NCT01375439
31 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584
32 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453
33 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738
34 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
35 Observational Program Neo-Penotran® Forte Completed NCT01335373
36 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
37 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
38 Epidemiological Study in Subjects With Vulvovaginal Candidiases Recruiting NCT03064789
39 Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis Recruiting NCT02859493
40 Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women Recruiting NCT01915251
41 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Not yet recruiting NCT03075046
42 Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M® Terminated NCT00915629
43 Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis Terminated NCT02345096

Search NIH Clinical Center for Vulvovaginitis

Cochrane evidence based reviews: vulvovaginitis

Genetic Tests for Vulvovaginitis

Anatomical Context for Vulvovaginitis

MalaCards organs/tissues related to Vulvovaginitis:

39
Testes, Colon, Neutrophil, Skin, B Cells, Breast, Lymph Node

Publications for Vulvovaginitis

Articles related to Vulvovaginitis:

(show top 50) (show all 744)
id Title Authors Year
1
Vulvovaginitis and diabetes. ( 28065975 )
2017
2
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. ( 28066940 )
2017
3
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association to clinical findings. ( 28052314 )
2017
4
Candida vulvovaginitis: A store with a buttery and a show window. ( 27687503 )
2017
5
ALS1 and ALS3 gene expression and biofilm formation in Candida albicans isolated from vulvovaginal candidiasis. ( 27376044 )
2016
6
Vulvovaginal gingival lichen planus: report of two cases and review of literature. ( 28042431 )
2016
7
Clinical Recommendation: Vulvovaginitis. ( 27969009 )
2016
8
Clinical and microbiologic characteristics of vulvovaginitis in Korean prepubertal girls, 2009-2014: a single center experience. ( 27004204 )
2016
9
Vulvovaginal Candidiasis in Pregnant Women and its Importance for Candida Colonization of Newborns. ( 27552787 )
2016
10
Personal Hygiene and Vulvovaginitis in Prepubertal Children. ( 26187769 )
2016
11
Syngonanthus nitens Bong. (Rhul.)-Loaded Nanostructured System for Vulvovaginal Candidiasis Treatment. ( 27556451 )
2016
12
Vulvovaginal laceration as a risk factor for uterine disease in postpartum dairy cows. ( 27016827 )
2016
13
Author's reply to comment on: is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 27988816 )
2016
14
Recurrent desquamative vulvovaginitis in a young woman. ( 26266812 )
2016
15
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 27393491 )
2016
16
Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. ( 27129474 )
2016
17
Microsatellite analysis of genotype distribution patterns of Candida albicans vulvovaginal candidiasis in Nanjing, China and its association with pregnancy, age and clinical presentation. ( 26861467 )
2016
18
Streptococcus pyogenes as the cause of vulvovaginitis and balanitis in children from Nis, Serbia. ( 27638252 )
2016
19
Surgical management of vulvovaginal agglutination due to lichenA planus. ( 27094966 )
2016
20
Clinical presentation, diagnosis and treatment of vulvovaginitis in girls: a current approach and review of the literature. ( 28083751 )
2016
21
Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device. ( 27957732 )
2016
22
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 28025698 )
2016
23
Candida nivariensis as a New Emergent Agent of Vulvovaginal Candidiasis: Description of Cases and Review of Published Studies. ( 26708316 )
2016
24
Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity. ( 27415762 )
2016
25
Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus. ( 27298383 )
2016
26
Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6A Months. ( 27206514 )
2016
27
Antifungal effects of Lavandula binaludensis and Cuminum cyminum essential oils against Candida albicans strains isolated from patients with recurrent vulvovaginal candidiasis. ( 27751723 )
2016
28
Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women. ( 27132409 )
2016
29
Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. ( 26991298 )
2016
30
Vulvovaginal-gingival syndrome and esophageal involvement in lichen planus. ( 26585852 )
2016
31
The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. ( 27073145 )
2016
32
Use of Platelet-rich Plasma for Vulvovaginal Autoimmune Conditions Like Lichen Sclerosus. ( 27975027 )
2016
33
Management of chronic vulvovaginal candidiasis: a long term retrospective study. ( 27250078 )
2016
34
Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. ( 27915337 )
2016
35
Genotyping and Persistence of Candida albicans from Pregnant Women with Vulvovaginal Candidiasis. ( 27882525 )
2016
36
Phospholipase and proteinase activities of Candida spp. isolates from vulvovaginitis in Iran. ( 27544321 )
2016
37
A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. ( 27838642 )
2016
38
The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. ( 27796932 )
2016
39
The Effects of Ozonated Olive Oil and Clotrimazole Cream for Treatment of Vulvovaginal Candidiasis. ( 27548492 )
2016
40
Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy. ( 27170259 )
2016
41
Clinical Significance and Characteristic Clinical Differences of Cytolytic Vaginosis in Recurrent Vulvovaginitis. ( 27300413 )
2016
42
Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil. ( 27304096 )
2016
43
Phospholipase and Aspartyl Proteinase Activities of Candida Species Causing Vulvovaginal Candidiasis in Patients with Type 2 Diabetes Mellitus. ( 26032358 )
2015
44
Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. ( 25416649 )
2015
45
Vulvovaginal candidiasis in pregnancy. ( 25916994 )
2015
46
Theriogenology Question of the Month. Vulvovaginitis or uterine, cervical, or vaginal neoplasia. ( 26642128 )
2015
47
Streptococcal vulvovaginitis in adults: Not a rare entity. ( 26515866 )
2015
48
Efficacy and safety of a single oral 150A mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan. ( 25887336 )
2015
49
Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. ( 25881537 )
2015
50
Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). ( 25711406 )
2015

Variations for Vulvovaginitis

Expression for Vulvovaginitis

Search GEO for disease gene expression data for Vulvovaginitis.

Pathways for Vulvovaginitis

Pathways related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 CCL11 CCL5 CXCL8 IL10
2
Show member pathways
12.96 CCL11 CCL5 CXCL8 IL10
3
Show member pathways
12.89 CCL11 CCL5 CXCL8 IL10
4
Show member pathways
12.41 CCL11 CXCL8 HSPD1 IL10
5
Show member pathways
11.98 CCL11 CCL5 CXCL8
6 11.79 CXCL8 HSPD1 IL10
7
Show member pathways
11.59 CCL11 CCL5 CXCL8
8 11.49 CCL11 CXCL8 IL10
9 11.44 CXCL8 IL10
10 11.34 CCL11 IL10
11 11.25 CXCL8 HSPD1
12 11.18 CXCL8 IL10
13 11.15 CCL11 IL10
14 11.13 CCL11 CCL5 CXCL8
15 10.82 CCL5 CXCL8 IL10
16 10.81 CCL5 CXCL8
17 10.15 CCL11 CCL5 CXCL8 IL10

GO Terms for Vulvovaginitis

Cellular components related to Vulvovaginitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 CCL11 CCL5 CXCL8 HSPD1 IL10

Biological processes related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.73 CCL11 CCL5 CXCL8 IL10
2 chemotaxis GO:0006935 9.69 CCL11 CCL5 CXCL8
3 response to glucocorticoid GO:0051384 9.58 HSPD1 IL10
4 positive regulation of endothelial cell proliferation GO:0001938 9.58 CCL11 IL10
5 cellular response to tumor necrosis factor GO:0071356 9.58 CCL11 CCL5 CXCL8
6 cellular response to interferon-gamma GO:0071346 9.57 CCL11 CCL5
7 response to activity GO:0014823 9.56 HSPD1 IL10
8 inflammatory response GO:0006954 9.56 CCL11 CCL5 CXCL8 IL10
9 monocyte chemotaxis GO:0002548 9.55 CCL11 CCL5
10 B cell proliferation GO:0042100 9.54 HSPD1 IL10
11 cellular response to fibroblast growth factor stimulus GO:0044344 9.52 CCL5 CXCL8
12 response to molecule of bacterial origin GO:0002237 9.49 CXCL8 IL10
13 positive regulation of macrophage activation GO:0043032 9.48 HSPD1 IL10
14 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.46 CCL5 CXCL8
15 neutrophil activation GO:0042119 9.37 CCL5 CXCL8
16 cellular response to interleukin-1 GO:0071347 9.33 CCL11 CCL5 CXCL8
17 eosinophil chemotaxis GO:0048245 9.32 CCL11 CCL5
18 chemokine-mediated signaling pathway GO:0070098 9.13 CCL11 CCL5 CXCL8
19 neutrophil chemotaxis GO:0030593 8.8 CCL11 CCL5 CXCL8

Molecular functions related to Vulvovaginitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.13 CCL11 CCL5 CXCL8
2 cytokine activity GO:0005125 8.92 CCL11 CCL5 CXCL8 IL10

Sources for Vulvovaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....